You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Relapsed/Refractory Multiple Myeloma: An Expert-Guided Tour Through New and Emerging Therapies

  • Authors: Peter Voorhees, MD; Krina K. Patel, MD, MSc; Saad Usmani, MD, MBA, FACP
  • CME Released: 10/28/2022
  • Valid for credit through: 10/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists and other healthcare providers (HCPs) involved in the care of patients with MM.

The goal of this activity is for the learner to better be able to improve the knowledge of hematologists/oncologists regarding approved and emerging therapies used in the management of relapsed/refractory (R/R) MM to ensure they can skillfully and safely integrate available therapeutic options in practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Emerging clinical data for R/R MM
    • Mechanism of action (MOA) of therapies for R/R MM
  • Have greater competence related to
    • Selecting novel therapies for R/R MM
  • Demonstrate greater confidence in their ability to
    • Determine which patients may be candidates for new myeloma treatment approaches


Medical Learning Institute, Inc., and Medscape, LLC are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.


  • Peter Voorhees, MD

    Professor of Medicine
    Atrium Health Levine Cancer Institute
    Wake Forest University School of Medicine
    Winston-Salem, North Carolina


    Peter Voorhees, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Bristol Myers Squibb; GlaxoSmithKline; Janssen; Pfizer; Sanofi
    Research funding from: AbbVie; GlaxoSmithKline; Janssen

  • Krina K. Patel, MD, MSc

    Associate Professor
    Department of Lymphoma/Myeloma
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas


    Krina K. Patel, MD, MSc, has the following relevant financial relationships:
    Consultant or advisor for: Arcellx; Bristol Myers Squibb; Celgene; Cellectis; Janssen; Karyopharm; Oncopeptides; Pfizer
    Contracted researcher for: Allogene; Bristol Myers Squibb; Cellectis; Celgene; Nektar; Precision Bio; Takeda

  • Saad Usmani, MD, MBA, FACP

    Chief of Myeloma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York


    Saad Usmani, MD, MBA, FACP, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Amgen; Bristol Myers Squibb; Celgene; EdoPharma; Genentech; Gilead; GlaxoSmithKline; Janssen; Oncopeptides; Sanofi; Seagen Inc., SecuraBio; SkylineDX; Takeda; TeneoBio
    Speaker or member of speakers bureau for: Amgen; Bristol Myers Squibb; Janssen; Sanofi
    Research funding from: Amgen; Array Biopharma; Bristol Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Merck; Pharmacyclics; Sanofi; Seagen Inc.; SkylineDX; Takeda


  • Mihai Surducan, PhD

    Medical Education Director, Medscape, LLC


    Mihai Surducan, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Peer Reviewer

The planners and content / peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies. 

Accreditation Statements

Presented through a collaboration between Medical Learning Institute and Medscape Education.

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Medscape, LLC. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medical Learning Institute, Inc., designates this enduring material for a maximum of 0.75  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Relapsed/Refractory Multiple Myeloma: An Expert-Guided Tour Through New and Emerging Therapies

Authors: Peter Voorhees, MD; Krina K. Patel, MD, MSc; Saad Usmani, MD, MBA, FACPFaculty and Disclosures

CME Released: 10/28/2022

Valid for credit through: 10/28/2023


Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print